BiotechTube
Pohl-Boskamp

Pohl-Boskamp

Hohenlockstedt, Germany
pohl-boskamp.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Pohl-Boskamp is a privately held, commercial-stage German pharmaceutical company with a century-long heritage, notably as the originator of Nitrolingual®. It has evolved from a traditional generic drug producer into an innovative player combining established therapeutics with a growing portfolio of digital health applications (DiGAs). The company's strategy leverages its strong brand management, in-house development and manufacturing, and strategic partnerships to address therapeutic areas including cardiology, otology, pulmonology, and pain management.

CardiologyOtology (Tinnitus)PulmonologyPain ManagementDermatology

Technology Platform

In-house pharmaceutical formulation/manufacturing and a dedicated commercialization platform for Digital Health Applications (DiGAs) in the German market.

Opportunities

Significant growth in the German Digital Health Application (DiGA) market, where Pohl-Boskamp has established an early-mover advantage in commercialization.
Expanding its portfolio of partnered DiGAs into new therapeutic areas presents a capital-efficient growth path.
The stable revenue from legacy brands like Nitrolingual® provides a foundation to fund these digital initiatives.

Risk Factors

High dependency on the regulatory and reimbursement policies of the German healthcare system, particularly for its DiGA business.
Intense competition in both the generic drug market and the emerging digital therapeutics space.
A relatively narrow late-stage pharmaceutical pipeline could limit long-term growth in its core drug business.

Competitive Landscape

In generics/branded generics, competes with large global generic firms (e.g., Teva, Sandoz) and other European mid-caps. In DiGA commercialization, competes with other marketing specialists, digital health agencies, and potentially large pharma companies building their own digital health units. Its differentiation lies in its integrated pharma heritage, trusted brand, and specific expertise in the German DiGA pathway.

More companies in Small Molecule Drugs →More companies in Germany →